title: Conversations in cardiology: bridging antiplatelet therapy before surgery.
abstract: Bridging for antiplatelet therapy remains a subject of debate with data favoring GP blockers but at a risk of bleeding. This Conversation in Cardiology addresses a key and often asked question about use of alternatives to P2Y12 agents in patients requiring surgery within 6 months after drug eluting stent implantation.
authors.affiliation: University California Irvine, Chief Cardiology, Long Beach Veterans Administration Heath Care System, Long Beach, California; University of California, Irvine Medical Center, Orange, California.
authors.forename: Morton J
authors.initials: MJ
authors.lastname: Kern
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Applegate
authors.forename: Malcolm
authors.initials: M
authors.lastname: Bell
authors.forename: Emmanouil S
authors.initials: ES
authors.lastname: Brilakis
authors.forename: Samuel M
authors.initials: SM
authors.lastname: Butman
authors.forename: Richard G
authors.initials: RG
authors.lastname: Bach
authors.forename: Prashant
authors.initials: P
authors.lastname: Kaul
authors.forename: Lloyd W
authors.initials: LW
authors.lastname: Klein
authors.forename: Mitchell W
authors.initials: MW
authors.lastname: Krucoff
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Moore
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Price
authors.forename: Sunil V
authors.initials: SV
authors.lastname: Rao
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
authors.forename: Barry F
authors.initials: BF
authors.lastname: Uretsky
mesh_terms: D003328:Coronary Thrombosis / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D016527:Drug Costs; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D019990:Perioperative Care; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics; D013514:Surgical Procedures, Operative / Q000191:economics; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists
keywords: antiplatelet therapy; stent thrombosis